Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2011

View Archived Issues

Additional data disclosed from ALLEGRO and BRAVO trials of laquinimod in RRMS

Initial treatment phase of rabeprazole trial in pediatric patients completed

Potential new target for MS therapy discovered at U.S. univeristy

Candidate vaccine for CDI-associated diarrhea is immunogenic and well tolerated

New therapeutic approach suggested for achalasia / News in Context

Pharmasset commences pivotal phase III program for interferon-free PSI-7977 regimen

Scientists at Amgen disclose new PI3K inhibitors

OncoTherapy Science patents novel PDZ-binding kinase inhibitors

Novel histone deacetylase inhibitors disclosed

AgonOx and MedImmune join to develop TNF receptor superfamily member 4 agonists

Array BioPharma and Genentech jointly synthesize new beta-secretase 1 inhibitors

Novel receptor-interacting protein 2 inhibitors prepared by GSK

Promising data disclosed from phase Ib trial of DB-959Na

Isis antisense drugs enter phase I development for type 2 diabetes

FDA sets PDUFA date for alogliptin and alogliptin/pioglitazone NDAs

Medivir reports final results from ASPIRE study

Furiex acquires exclusive license to develop MuDelta

FDA approves highly specific HPV assay

ExonHit extends strategic collaboration with Allergan

Resverlogix begins dosing in ASSURE study

FDA recommends approval of Vytorin in patients with predialysis chronic kidney disease

Meda files MAA for Dymista in Europe

Immunomedics resumes clivatuzumab tetraxetan study

Clonidine Lauriad receives European orphan drug status

Nuron Biotech starts phase III trial of NU-100 in MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...